[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"sars-cov-2\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:sars-cov-2":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,14,0,[8,46,76,123,137,174,200,225,250,276,296,322,351,372],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100053348","phase-1-kisspeptin-to-quantify-gnrh-neuronal-function-in-health-and-disease-100053348",false,"NCT07224490","Kisspeptin to Quantify GnRH Neuronal Function in Health and Disease","Inclusion Criteria\n\n* Female (ages 18-45 years) or Male (ages 18-60 years)\n* No current or recent use of a medication (including hormonal replacement) that, in the opinion of a study investigator, can modulate the reproductive axis or willing to complete an appropriate washout for that particular medication and its method of administration\n* For women, negative serum hCG pregnancy test\n* For cases, diagnosis of post-covid-19 syndrome\n* For controls, history of prior covid infection but no diagnosis of post-covid-19 syndrome\n\nExclusion Criteria\n\n* Any condition (medical, mental, or behavioral) that, in the opinion of a study investigator, would likely interfere with participation in\u002Fcompletion of the protocol or the interpretation of results\n* Active use of illicit drugs (not including marijuana)\n* For women,\n* Pregnant\n* Trying to become pregnant during protocol participation\n* Breast feeding\n* Surgical or natural menopause","ALL","18 Years","60 Years",{"count":19,"type":20},40,"ESTIMATED","INTERVENTIONAL",[23],"PHASE1","The objective of this protocol is to use a case-control paradigm to compare the response to an intravenous administration of kisspeptin in individuals with and without post-covid-19 syndrome. The study subjects will receive a single bolus of kisspeptin.",[26,27,28,29],"Reproductive Disorder","Neurodegeneration","SARS-CoV 2","Long COVID",[31,27,28,32,29],"Reproductive disorder","Kisspeptin","RECRUITING","2026-07-09",{"date":36,"type":37},"2026-07-13","ACTUAL",{"date":39,"type":37},"2026-03-10",{"date":41,"type":20},"2030-05",{"name":43,"class":44},"Stephanie B. Seminara, MD","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":21,"phases":55,"briefSummary":57,"conditions":58,"keywords":62,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":45},"100585813","phase-3-dapagliflozin-for-long-covid-syndrome-100585813","NCT06907251","Dapagliflozin for Long COVID Syndrome","DALCO","Inclusion Criteria:\n\n* 18 years of age or older and willing and able to provide informed consent\n* Patients with a history of positive COVID-19 test (polymerase chain reaction or rapid test) or have been diagnosed with COVID-19 by a health care provider.\n* New or persistent symptoms at least 12 weeks from infection and present for at least 8 weeks that is not explained by an alternative diagnosis (64).\n* Women of childbearing potential (WOCBP) who, if sexually active, are willing to use to use at least one highly effective methods of contraception throughout the study.\n\nExclusion Criteria:\n\n* History of diabetes\n* Prior heart failure\n* Weight loss treatment with glucagon-like peptide-1 receptor agonists (e.g. liraglutide, semaglutide)\n* Pregnancy or planned pregnancy in the next 12 months. We will ask WOCBP about the possibility of pregnancy at the time of screening and if so, then pregnancy testing will be offered. If testing is declined in this instance, then they will be excluded from the study.\n* Women who are breastfeeding\n* Severe renal impairment (eGFR\\\u003C30mL\u002Fmin1.73m2)\n* Known history of allergy or hypersensitivity to dapagliflozin\n\nExclusion for optional MRI portion of the protocol:\n\n\\- Any contraindication to MRI",{"count":54,"type":20},192,[56],"PHASE3","This is a randomized, placebo-controlled study. Patients with long COVID will be randomized to receive dapagliflozin or placebo for 12 months.",[59,60,61],"COVID - 19","Long COVID Syndrome","SARS CoV-2",[63,64,65],"Covid-19","Long Covid syndrome","sars cov-2","NOT_YET_RECRUITING","2026-06-30",{"date":69,"type":37},"2026-07-01",{"date":71,"type":20},"2026-09-01",{"date":73,"type":20},"2029-06-30",{"name":75,"class":44},"Ottawa Heart Institute Research Corporation",{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":21,"phases":85,"briefSummary":87,"conditions":88,"keywords":94,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":122},"100568680","phase-1-study-on-safety-and-efficacy-of-two-doses-of-prs-ck-storm-in-the-modulation-of-the-cytokine-storm-in-patients-with-acute-respiratory-infection-caused-by-sars-cov-2-influenza-a-influenza-b-and-respiratory-syncytial-virus-rsv-100568680","NCT06684379","Study on Safety and Efficacy of Two Doses of PRS CK STORM in the Modulation of the Cytokine Storm in Patients With Acute Respiratory Infection Caused by SARS-Cov-2, Influenza A, Influenza B and Respiratory Syncytial Virus (RSV)","Double-blind, Randomized, Placebo-controlled, Pilot Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of Two Doses of a Conditioned Medium From a Co-culture of M2-macrophages and Fat-derived Mesenchymal Cells (PRS CK STORM) in the Modulation of the Cytokine Storm in Patients With Acute Respiratory Infection Caused by SARS-Cov-2, Influenza A, Influenza B and Respiratory Syncytial Virus (RSV)","Inclusion Criteria:\n\n1. Signed informed consent by the participant or legal representative prior to the initiation of any study-specific procedure.\n2. Males and females aged ≥ 18 years old at the time of the consent.\n3. Confirmed diagnosis of SARS-CoV-2, influenza virus A, influenza virus B or RSV pneumonia by positive RT-PCR (results of a PCR prior to screening will be valid only if the PCR has been done for all 4 viruses and in 3 days prior to the screening visit). PCR will include the analysis of SARS-Cov-2, influenza A, influenza B and RSV.\n4. Diagnosis of systemic inflammatory response syndrome (SIRS), defined by the satisfaction of any two of the criteria below:\n\n   1. Body temperature over 38 ºC or under 36 ºC.\n   2. Heart rate greater than 90 beats\u002Fminute.\n   3. Respiratory rate higher than 20 breaths\u002Fmin or PaCO2 lower than 32 mmHg.\n   4. Leukocyte count higher than 12000\u002FμL, lower than 4000\u002FμL or over 10% immature forms or bands.\n5. Need for oxygen therapy.\n6. Female participants must be, either surgically sterilized or at least 1 year postmenopausal (confirmed by follicle-stimulating hormone \\[FSH\\] more than 20 international units \\[Ius\\] only for women under 54) or using adequate birth control (hormonal contraception, intrauterine contraceptive device, double barrier methods \\[condom with spermicide, diaphragm with spermicide, or condom and diaphragm\\]) or sexual abstinence for up to 90 days after the last treatment administration. Male participants must be willing to use barrier contraception (condom) for up to 90 days after the last treatment administration.\n\nExclusion Criteria:\n\n1. Failure to perform screening or baseline examinations.\n2. Body Mass Index (BMI) more than or equal to 35.\n3. Irreversible critical condition, as assessed by the investigator.\n4. Active autoimmune diseases or severe immunosuppression, unless stable and controlled for at least 3 months prior to the inclusion in the study.\n5. Clinically significant, advanced or unstable disease that may interfere with primary or secondary variable evaluations, may bias the clinical assessment, such as:\n\n   1. Liver function test abnormalities or other signs of hepatic insufficiency not justified by a pulmonary acute inflammation process: Aspartate transaminase (AST), alanine transaminase (ALT) more than 3 per upper limit of the reference range, total bilirubin more than or equal to 2 mg\u002FdL; except for subjects with isolated elevation of indirect bilirubin relating to Gilbert syndrome.\n   2. Renal insufficiency (serum creatinine more than 2 mg\u002FdL (more than 150 μmol\u002FL) and creatinine clearance less than 30 (according to Cockcroft-Gault formula).\n   3. Myocardial infarction, unstable angina, heart failure within 3 months before screening.\n   4. Bradycardia (heartbeat less than 50\u002Fmin).\n   5. Atrioventricular block (type II \u002F Mobitz II and type III), congenital long QT syndrome, sinus node dysfunction or prolonged QTcF interval (males more than 450 msec and females more than 470 msec using Fridericia's formula: QTc = QT\u002F RR\\^2 ).\n   6. Uncontrolled diabetes mellitus (blood glucose level above 500 mg\u002FdL) at the time of admission.\n   7. Malignant tumors within the last 5 years, unless stable during that time. Skin malignancies (other than melanoma) and indolent prostate cancer are excluded from this criterion.\n   8. Metastases.\n   9. Human Immunodeficiency Virus (HIV), HBV \\[hepatitis B surface antigen (HBs Ag) positive (+), or detected sensitivity on the HBV deoxyribonucleic acid (DNA), polymerase chain reaction (PCR) qualitative test for hepatitis B core antibody (HBc Ab) positive subjects\\] or HCV \\[HCV ribonucleic acid (RNA) detectable in any subject with positive anti-HCV antibody (HCV Ab)\\].\n6. Inability to comply with the study and monitoring procedures.\n7. Pregnant and breastfeeding females (pregnancy test positive).\n8. Suspected or known active drug or alcohol abuse.\n9. Enrollment in another investigational drug study within 1 month before the screening\n10. Subject who has any condition, including any psychological or psychiatric condition, in the opinion of the Investigator, would compromise the safety of the subject or the quality of the data and renders the subject an unsuitable candidate for the study.",{"count":84,"type":20},50,[23,86],"PHASE2","The purpose of this clinical trial is to evaluate the safety, tolerability and efficacy of two doses (dose A and dose B) of Standardized Conditioned Medium Obtained by Coculture of M2-macrophages and fat-derived Mesenchymal Stromal Cells (PRS CK STORM) in the modulation of the cytokine storm in participants with acute respiratory infection caused by SARS-Cov-2, influenza A, influenza B and respiratory syncytial virus (RSV) in need for oxygen therapy.\n\nThe main questions it aims to answer are:\n\n* Are both doses of PRS CK STORM (dose A and dose B) safe as an intravenous drug to modulate inflammatory processes, such as the cytokine storm in participants with SIRS caused by SARS-Cov-2, influenza A, influenza B and RSV?\n* Are both doses of PRS CK STORM (dose A and dose B) effective as an intravenous drug to modulate SIRS-associated cytokine storm caused by SARS-Cov-2, influenza A, influenza B and RSV compared to the control group?\n* What are the anti-inflammatory and pro-inflammatory cytokine profiles after treatment with two different doses of PRS CK STORM in participants with SIRS caused by SARS-Cov-2, influenza A, influenza B and RSV?\n\nResearchers will compare both doses of PRS CK STORM with the control group to test whether the anti-inflammatory action of PRS CK STORM is safe and effective in modulating the cytokine storm for the treatment of SIRS caused by SARS-Cov-2, influenza A, influenza B and RSV. In addition, the anti-inflammatory and pro-inflammatory cytokine profiles after treatment PRS CK STORM compared to placebo group in these participants will be also studied.",[89,90,91,92,93],"SARS-CoV-2","Influenza, Human","Respiratory Syncytial Virus Infections","Respiratory Distress Syndrome","Systemic Inflammatory Response Syndrome",[95,96,97,98,99,100,101,102,103,104,105,106,107,108,109,110,111,93],"SARS-CoV-2 infection","Causing atypical respiratory disease (COVID-19)","2019 Novel Coronavirus","COVID-19 Virus","SARS Coronavirus 2","COVID-19-associated cytokine storm","Lung Diseases","Pneumonia","M2-macrophages","Mesenchymal cells","Influenza A Virus","Influenza B Virus","RSV Infection","Acute Respiratory Distress Syndrome","ARDS, Human","Respiratory Distress Syndrome, Acute","Cytokine storm","2026-06-05",{"date":114,"type":37},"2026-06-10",{"date":116,"type":37},"2024-10-02",{"date":118,"type":20},"2026-10-02",{"name":120,"class":121},"PEACHES BIOTECH","INDUSTRY",3,{"id":124,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":125,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":126,"targetDuration":4,"studyType":21,"phases":127,"briefSummary":128,"conditions":129,"keywords":130,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":134,"completionDateStruct":135,"leadSponsor":136,"locationsCount":45},"100610200","Inclusion Criteria\n\n* Female (ages 18-45 years) or Male (ages 18-60 years)\n* Normal blood pressure (systolic BP \\\u003C 140 mm Hg, diastolic \\\u003C 90 mm Hg)\n* Hemoglobin no less than 0.5 g\u002FdL below the lower limit of the sex specific reference range\n* No current or recent use of a medication (including hormonal replacement) that, in the opinion of a study investigator, can modulate the reproductive axis or willing to complete an appropriate washout for that particular medication and its method of administration\n* For women, negative serum hCG pregnancy test\n* For cases, diagnosis of post-covid-19 syndrome\n* For controls, history of prior covid infection but no diagnosis of post-covid-19 syndrome\n\nExclusion Criteria\n\n* Any condition (medical, mental, or behavioral) that, in the opinion of a study investigator, would likely interfere with participation in\u002Fcompletion of the protocol\n* Excessive alcohol consumption (\\>10 drinks\u002Fweek)\n* Active use of illicit drugs\n* For women,\n* Pregnant\n* Trying to become pregnant during protocol participation\n* Breast feeding\n* History of any of the following: bilateral oophorectomy (ovaries were removed), breast cancer, thromboembolic disease, coronary artery disease, stroke, thrombophilic disorders, or undiagnosed abnormal genital bleeding",{"count":19,"type":20},[23],"The objective of this protocol is to use a case-control paradigm to compare the response to an intravenous administration of kisspeptin in individuals with and without post-covid-19 syndrome. The study subjects will receive a single bolus of kisspeptin.\n\nThis study will utilize the technique of frequent blood sampling (q10 minutes) to provide detailed neuroendocrine characterization of endogenous LH secretion before and after kisspeptin administration. This frequency of blood sampling is required to define the features of LH pulses.",[26,27,28,29],[31,27,28,32,29],"2026-05-16",{"date":133,"type":37},"2026-05-19",{"date":39,"type":37},{"date":41,"type":20},{"name":43,"class":44},{"id":138,"slug":139,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":4,"eligibilityCriteria":143,"healthyVolunteers":144,"sex":15,"minAge":145,"maxAge":4,"enrollmentInfo":146,"targetDuration":4,"studyType":21,"phases":148,"briefSummary":150,"conditions":151,"keywords":152,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":165,"startDateStruct":167,"completionDateStruct":169,"leadSponsor":171,"locationsCount":173},"100561060","phase-4-a-study-to-investigate-the-immunogenicity-and-safety-of-mrna-covid-19-variant-containing-vaccine-formulations-100561060","NCT06585241","A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations","A Phase 3b\u002F4, Open-label Study to Assess the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations","Key Inclusion Criteria:\n\n* mRNA-1273.167 and mRNA-1273.712: Previously vaccinated adults aged ≥18 years\n* mRNA-1273.251: Participants ≥65 years of age, ≥12 to \\\u003C65 years of age, or ≥6 months to \\\u003C12 years of age with at least 1 risk factor for severe outcomes from COVID-19.\n* mRNA-1273.261: ≥65 years of age at the time of signing the informed consent or ≥18 to \\\u003C65 years of age at the time of signing the informed consent with at least 1 risk factor for severe outcomes from COVID-19.\n* Able to comply with study procedures based on the assessment of the Investigator.\n* Female participants of childbearing potential may be enrolled in the study if the participant fulfills all the following criteria:\n\n  * Has a negative pregnancy test at the Screening Visit and on the day of vaccination prior to vaccine dose being administered on Day 1.\n  * Has practiced adequate contraception or has abstained from all activities that could result in pregnancy for at least 28 days prior to the first dose.\n  * Has agreed to continue adequate contraception through 28 days following vaccine administration.\n\nKey Exclusion Criteria:\n\n* History of SARS-CoV-2 infection within 3 months prior to enrollment for mRNA-1273.167 and mRNA-1273.712 or within up to 6 months prior to enrollment for mRNA-1273.251 and mRNA-1273.261.\n* Is acutely ill or febrile (temperature 38.0°Celsius\u002F100.4°Fahrenheit) less than 72 hours prior to or at the Screening Visit or Day 1. Participants meeting this criterion may be rescheduled within the Screening window.\n* History of a diagnosis or condition that, in the judgment of the Investigator, is clinically unstable, or may affect participant safety, assessment of study endpoints, assessment of immune response, or adherence to study procedures.\n* History of anaphylaxis or severe hypersensitivity reaction requiring medical intervention after receipt of any mRNA vaccine or therapeutic or any components of an mRNA vaccine or therapeutic.\n* Receipt of COVID-19 vaccine within 3 months prior to enrollment for mRNA-1273.167 and mRNA-1273.712 or within 6 months prior to enrollment for mRNA-1273.251 and mRNA-1273.261.\n* Receipt of any licensed non-COVID-19 vaccine within 14 days (inactivated vaccine, pediatric) or 28 days before or planned receipt within 14 days (pediatric) or 28 days after the study intervention, except an influenza vaccine, which may be given at least 7 days before (pediatric) or 14 days before or after receipt of the study intervention.\n* Receipt of systemic immunosuppressants or immune-modifying drugs for \\>14 days total (within 6 months prior to Screening for mRNA-1273.167 and mRNA-1273.712 or within 180 days prior to Screening for mRNA-1273.251 and mRNA-1273.261) or is anticipating the need for immunosuppressive treatment at any time during participation in the study.\n* Receipt of systemic immunoglobulins, long-acting biological therapies that affect immune (pediatric) responses, or blood products (within 3 months prior to Screening for mRNA-1273.167 and mRNA-1273.712 or within 90 days prior to the Screening for mRNA-1273.251 and mRNA-1273.261) or plans for receipt during the study.\n* Has donated ≥450 milliliters of blood products within 28 days prior to the Screening Visit or plans to donate blood products during the study.\n\nOther protocol-defined inclusion\u002Fexclusion criteria may apply.",true,"6 Months",{"count":147,"type":20},1144,[149],"PHASE4","The purpose of this study is to investigate the immunogenicity and safety of mRNA COVID-19 variant-containing vaccine formulations against the vaccine-matched variants and newly emerged variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).",[89],[153,154,89,155,156,157,158,159,160,161,162,163],"mRNA-1273","mRNA-1273 vaccine","SARS-CoV-2 Vaccine","Coronavirus","Virus Diseases","Messenger RNA","COVID-19","COVID-19 Vaccine","Variant","Moderna","Pediatric","2026-03-23",{"date":166,"type":37},"2026-03-27",{"date":168,"type":37},"2024-09-09",{"date":170,"type":20},"2026-12-31",{"name":172,"class":121},"ModernaTX, Inc.",6,{"id":175,"slug":176,"hasResults":11,"nctId":177,"briefTitle":178,"officialTitle":179,"acronym":4,"eligibilityCriteria":180,"healthyVolunteers":144,"sex":15,"minAge":16,"maxAge":181,"enrollmentInfo":182,"targetDuration":4,"studyType":21,"phases":184,"briefSummary":185,"conditions":186,"keywords":187,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":192,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":198,"locationsCount":45},"100624969","phase-1-effect-of-cov2-vaccine-formulation-on-the-ability-to-generate-antibodies-against-coronavirus-that-causes-covid-19-100624969","NCT07416539","Effect of COV2 Vaccine Formulation on the Ability to Generate Antibodies Against Coronavirus That Causes COVID-19","A Phase 1a, Single-Blind, Randomized Comparative Clinical Trial Evaluating the Impact of Vaccine Formulation on the Safety and Immunogenicity of the COV2 Vaccine in Healthy Adults","Inclusion criteria\n\n* Has voluntarily signed the written informed consent\n* Male or female aged ≥18 to ≤75 years\n* Good general health based upon the results of the medical history, laboratory tests, physical examination, ENT clinical examination, and vital signs as assessed by the investigator\n* Prior vaccination with at least two doses of any COVID-19 vaccine with last dose obtained ≥180 days before the planned baseline (Day 0) visit\n* Has a personal smartphone, tablet or computer with internet access, and is considered willing and able to report the data in the ePRO and to comply with the reporting timelines\n* Willing and able to comply with the instructions to participants\n* Not of childbearing potential or willing and able to use a highly effective contraception method consistently and correctly during the entire trial\n\nExclusion criteria\n\n* Pregnant, planning to become pregnant, or breastfeeding women\n* Received any investigational drug \\\u003C 180 days prior baseline\n* Antigen positivity or PCR confirmed SARS-CoV-2 infection less than 180 days apart from screening or during screening and\u002For baseline\n* Any SARS-CoV vaccination was administrated \\\u003C 180 days prior the planned baseline (Day 0) visit\n* Any other vaccination within 60 days prior the planned baseline (Day 0) visit\n* Administration of immunoglobulins or blood products within 90 days prior baseline\n* Current use of immunosuppressant medication (except topical and inhaled steroids, which are permitted in indications not prohibited in the exclusion criteria)\n* Use of steroid nasal sprays within 30 days prior to screening\n* Use of any oral or nasal decongestants within 7 days prior to screening\n* Any confirmed or suspected immunodeficient state\n* Chronic respiratory diseases (except treatment -controlled asthma)\n* Severe chronic cardiovascular and endocrinological diseases (e.g., medicine or insulin treated diabetes), liver and renal insufficiency or serious psychiatric diseases\n\n  \\- Medication for elevated cholesterol or blood pressure or dietary treated diabetes or hypothyreosis are not exclusion criteria\n* Any diagnosed disease or abnormality in the nasal or upper respiratory tract, such as acute\u002Fchronic rhinosinusitis; nasal polyposis; mucosal pathology or tumor of nasal cavity, pharynx or nasopharynx; significant obstructive nasal deformity; recurrent epistaxis; sleep apnea; anosmia\n\n  \\- History of adenoidectomy and\u002For tonsillectomy are not exclusion criteria\n* Severe obesity (BMI ≥ 35)\n* Cancer treated within 5 years\n* Known allergy\u002Fhypersensitivity to any ingredients of the COV2 vaccine\n* Previous anaphylactic reaction\n* Any clinically significant abnormal finding in the screening laboratory tests\n* Inability to sign ICF or to understand and comply with trial related instructions and requirements\n* Individuals who are employees of, or directly affiliated with, the sponsor, or site staff or their immediate family members.","75 Years",{"count":183,"type":20},20,[23],"This is a Phase 1a, single-country, single-centre, single-blinded, COV2 vaccine formulation randomized trial designed to investigate and compare the safety and immunogenicity of two COV2 vaccine formulations. COV2 is a nasal, investigational vaccine against COVID-19, based on a serotype 5 adenoviral vector producing modified SARS-CoV-2 spike protein.\n\nParticipants will receive one of the two COV2 formulations in two doses on Day 0 and Day 28.\n\nThis trial consists of two parts; Part 1 is a vaccination phase assessing safety and immunogenicity and Part 2 is a long-term immunogenicity follow-up assessing persistence of immune response.",[59,61],[188,159,189,190],"nasal vaccine","adenoviral vector-based vaccines","Sars CoV-2","2026-02-18",{"date":193,"type":37},"2026-02-20",{"date":195,"type":37},"2026-02-10",{"date":197,"type":20},"2026-11",{"name":199,"class":121},"Rokote Laboratories Finland Oy",{"id":201,"slug":202,"hasResults":11,"nctId":203,"briefTitle":204,"officialTitle":205,"acronym":206,"eligibilityCriteria":207,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":208,"targetDuration":4,"studyType":210,"phases":4,"briefSummary":211,"conditions":212,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":215,"lastUpdatePostDateStruct":216,"startDateStruct":218,"completionDateStruct":220,"leadSponsor":222,"locationsCount":224},"100392621","covid-19---study-of-the-kinetics-of-the-immune-response-during-the-intensive-care-unit-stay-in-adult-patients-infected-with-sars-cov-2-multicentric-non-interventional-study-100392621","NCT04392401","COVID-19 - Study of the Kinetics of the Immune Response During the Intensive Care Unit Stay in Adult Patients Infected With SARS-CoV-2: Multicentric Non Interventional Study","Study of the Kinetics of the Immune Response During the Intensive Care Unit Stay in Adult Patients Infected With SARS-CoV-2: Multicentric Non Interventional Study","RICO","Inclusion Criteria:\n\n1. Man or woman aged 18 or over,\n2. Hospitalization in intensive care for Sars-Cov-2 pneumopathy,\n3. First hospitalization in intensive care unit,\n4. Positive diagnosis of SARS-CoV2 infection carried out by PCR or by another approved method in at least one respiratory sample,\n5. Sampling in the first 24 hours after admission to intensive care unit (D0 \u002F D1) feasible,\n6. Patient or next of kin who has been informed of the terms of the study and has not objected to participating.\n\nExclusion Criteria:\n\n1. Pregnant or lactating woman,\n2. Person placed under legal protection,",{"count":209,"type":20},200,"OBSERVATIONAL","Infection with the SARS-CoV-2 coronavirus (COVID-19) has recently been identified as a pandemic due to the speed and global scale of its transmission. In Auvergne-Rhône-Alpes region (AURA), the epidemic began in February 2020 and the number of infected people is still important. Between 15 and 20% of COVID-19 patients develop an acute respiratory distress syndrome (ARDS) leading to their hospitalization in intensive care. Their clinical progression can be rapidly harmful with the development of severe ARDS associated with an increased risk of death.\n\nPreliminary data on the immune response of COVID-19 patients describe the induction of a moderate inflammatory response and the occurrence of major progressive lymphopenia over time associated with potential immunosuppression. Up to 50% of secondary infections are reported in deceased COVID-19 patients. However, no prospective study has exhaustively described the kinetics of the immune response of COVID-19 patients in intensive care.\n\nThe precise description of the immune response over time in adult patients with a proven infection with the SARS-CoV-2 virus and the study of the relation between this response and the increased risk of organ failure (severe ARDS), death or nosocomial infection will allow us to better understand the pathophysiology of the immune response induced by COVID-19 in order to (i) identify new therapeutic strategies targeting the host response in patients in intensive care (ii) to develop biological markers to stratify patients for future clinical trials evaluating these immunoadjuvant treatments in COVID-19.",[213,214],"Intensive Care Unit","SARS-Cov-2","2025-12-09",{"date":217,"type":37},"2025-12-17",{"date":219,"type":37},"2020-05-11",{"date":221,"type":20},"2026-04",{"name":223,"class":44},"Hospices Civils de Lyon",8,{"id":226,"slug":227,"hasResults":11,"nctId":228,"briefTitle":229,"officialTitle":230,"acronym":231,"eligibilityCriteria":232,"healthyVolunteers":11,"sex":15,"minAge":233,"maxAge":4,"enrollmentInfo":234,"targetDuration":4,"studyType":210,"phases":4,"briefSummary":236,"conditions":237,"keywords":239,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":241,"lastUpdatePostDateStruct":242,"startDateStruct":244,"completionDateStruct":246,"leadSponsor":248,"locationsCount":45},"100396902","determinants-of-sars-severe-acute-respiratory-syndrome-cov2-covid-19-persistence-after-convalescence-100396902","NCT04448145","Determinants of SARS (Severe Acute Respiratory Syndrome)-COV2 (COVID-19) Persistence After Convalescence","Characterizing SARS-CoV-2 Persistence in Host Reservoirs, Post-viral Sequelae, and Associations With Host and Viral Determinants in a Cohort of Convalescent COVID-19 Cases","C-PIC","Inclusion Criteria:\n\n* Laboratory confirmed SARS-CoV-2 using currently available laboratory testing techniques (e.g.,RT-PCR, Immunoglobulin M (IgM) \u002FIgG) or clinical history compatible with a COVID-19 like illness(fever, cough, shortness of breath).\n* Negative participants with no known prior COVID-19 diagnosis or COVID vaccine\n* At least 7 years of age\n* Participants are eligible to provide semen and breast milk samples if they are 18 years of age or older\n\nExclusion Criteria:\n\n* Age \\\u003C7\n* Intercurrent conditions that in the opinion of the investigator would confound the findings of the study.","7 Years",{"count":235,"type":20},800,"The 2019-2020 COVID-19 pandemic is the largest outbreak in recent history. It is not known how long after someone gets sick with COVID-19 and recovers that they can still infect other people. It is also not known how quickly people make antibodies against the virus, which help clear infection from the body. The investigators will enroll 300 people who had COVID-19 based on lab testing or confirmed exposure to participate. An additional 25 participants who have never tested positive for COVID and have not had the vaccine will be enrolled as negative controls. Participants will complete a survey at enrollment. The investigators will also collect blood, nose swab, saliva, stool, semen, and breast milk to test for the virus. The investigators will ask participants to complete a survey and give specimens up to 12 times over 24 months. This information will be used to study how long the virus can live in different parts of the body, antibody development, and post-infectious complications. The investigators hope that this information will allow medical and public health providers to make recommendations to better care for patients in the convalescent phase of COVID-19 infection.",[159,238,28],"Corona Virus Infection",[240],"Novel Coronavirus","2025-11-03",{"date":243,"type":37},"2025-11-05",{"date":245,"type":37},"2020-03-26",{"date":247,"type":20},"2026-09",{"name":249,"class":44},"Columbia University",{"id":251,"slug":252,"hasResults":11,"nctId":253,"briefTitle":254,"officialTitle":255,"acronym":4,"eligibilityCriteria":256,"healthyVolunteers":144,"sex":15,"minAge":16,"maxAge":257,"enrollmentInfo":258,"targetDuration":4,"studyType":21,"phases":259,"briefSummary":260,"conditions":261,"keywords":263,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":267,"lastUpdatePostDateStruct":268,"startDateStruct":270,"completionDateStruct":272,"leadSponsor":274,"locationsCount":45},"100586777","phase-2-mrna-covid-19-vaccine-immune-response-comparisons-using-different-delivery-routes-100586777","NCT06919796","mRNA Covid-19 Vaccine Immune Response Comparisons Using Different Delivery Routes","Systems Biology of a mRNA Vaccine Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Given Via Intradermal (ID) Injection Using Tropis Needle-Free Injection System (NFIS) or Intramuscular (IM) Injection Using Needle and Syringe","Inclusion Criteria:\n\n1. Able to understand and give informed consent\n2. Adults aged 18 to 50 years old.\n3. Willing and able to comply with all scheduled visits, vaccination, and laboratory tests.\n4. Determined by investigator to be in good health based on medical history, targeted physical exam and laboratory testing.\n5. Participants with pre-existing stable chronic medical conditions defined as condition not requiring significant change in therapy or hospitalization for worsening disease within 4 weeks from enrollment, can be included at the discretion of the investigator.\n6. For women of childbearing potential: willing to engage in effective methods of contraception starting at least 30 days prior to enrollment and for the duration of the study.\n\nExclusion Criteria:\n\n1. Receipt of blood products 90 days prior to study entry and for the duration of the study.\n2. Volunteers who donated blood 60 days before screening OR will donate blood on or before D30.\n3. Receipt of any experimental agents within 30 days or 5 half-lives whichever is longer prior to vaccination and for the duration of the study.\n4. Receipt of any licensed vaccine within 60 days prior to study vaccination or planned receipt of any vaccine until 60 days later as well as receipt of COVID-19 vaccine for the duration of the study.\n5. Receipt of a COVID-19 vaccine or confirmed COVID-19 in the past year or positive SARS-CoV-2 antigen test on vaccination day.\n6. Chronic medical problems including (but not limited to) autoimmune disease, severe gastrointestinal disease, and grade 4 hypertension.\n7. Any diseases or conditions that put individuals at increased risk for severe COVID-19 illness, including: type 1 or 2 diabetes, chronic lung disease (including moderate to severe asthma, bronchiectasis, bronchopulmonary dysplasia, chronic obstructive pulmonary disease (COPD), interstitial lung disease including idiopathic pulmonary fibrosis, pulmonary embolism, or pulmonary hypertension), cystic fibrosis, dementia, Parkinson's disease, cerebrovascular disease, chronic liver disease, chronic kidney disease (any stage), heart conditions, hemoglobin blood disorders (sickle cell disease, thalassemia).\n8. BMI \\> 40 kg\u002Fm2\n9. Any potentially immune mediated disease (with the exception of well controlled hypothyroidism).\n10. Alcohol or drug abuse and psychiatric conditions that in the opinion of the investigator would preclude compliance with the trial or interpretation of safety or endpoint data.\n11. Impaired immune function or chronic infections including (but not limited to) HIV, hepatitis B or C; organ transplant; active cancer or any history of hematologic cancer; receipt of chemotherapy, radiation therapy (past 12 months) or any other potentially immunosuppressive therapy \\[i.e. received oral, intramuscular or intravenous systemic immunosuppressants, or immune modifying drugs for \\>14 days in total within 6 months prior to any study vaccine dose (for corticosteroids ≥ 20 mg\u002Fday of prednisone equivalent). Note: Topical medications are allowed.\\], congenital immunodeficiency, anatomical or functional asplenia.\n12. Pregnancy or breast feeding or planned pregnancy for the duration of the study.\n13. Severe reactions to prior vaccination with Covid-19 mRNA vaccine or any of its components, including anaphylaxis.\n14. History of Guillain Barré syndrome or myopericarditis.\n15. Volunteers with any acute illness, including any fever (\\> 100.4 F \\[\\> 38.0C\\], regardless of the route) within 3 days prior to study entry.\n16. Social, occupational, or any other condition that in the opinion of the investigator might interfere with compliance with the study and vaccine evaluation.","50 Years",{"count":19,"type":20},[86],"The purpose of this study is to determine if immune responses differ when the mRNA COVID-19 vaccine is given through different delivery methods, including a needle-free injection system, or via intramuscular injection using needle and syringe",[262,61],"Evaluate Immune Responses Following mRNA COVID-19 Vaccine Administration Through Different Delivery Routes in Healthy Volunteers",[264,265,266],"Tropis ID","Needle-free injection","Tropis","2025-04-10",{"date":269,"type":37},"2025-04-15",{"date":271,"type":20},"2025-05-01",{"date":273,"type":20},"2026-11-25",{"name":275,"class":121},"PharmaJet, Inc.",{"id":277,"slug":278,"hasResults":11,"nctId":279,"briefTitle":280,"officialTitle":280,"acronym":4,"eligibilityCriteria":281,"healthyVolunteers":144,"sex":15,"minAge":16,"maxAge":282,"enrollmentInfo":283,"targetDuration":4,"studyType":210,"phases":4,"briefSummary":284,"conditions":285,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":287,"lastUpdatePostDateStruct":288,"startDateStruct":290,"completionDateStruct":292,"leadSponsor":294,"locationsCount":45},"100586381","immunotherapy-care-and-prevention-of-infectious-and-tumoral-diseases-immunohub-100586381","NCT06914635","Immunotherapy: Care and Prevention of Infectious and Tumoral Diseases (ImmunoHUB)","Inclusion Criteria:\n\nLine 1: - Age \\>18 at time of signing informed consent form\n\n* Signed informed consent form Line 2: - Primery liver tumor\n* Age \\>18 at time of signing informed consent form\n* Signed informed consent form\n\nExclusion Criteria:\n\nLine 1: - Active or history of neoplastic malignancy\n\n* Active autoimmune disease ongoing treatment with immunosuppressive therapy\n* Evidence of positive HIV, HCV, HBV test\n* Diabetes\n* Failure to sign informed consent form Line 2: - Concomitant diseases with life expectancy of less than 12 months\n* Chronic autoimmune or inflammatory diseases\n* Treatment with atezolizumab, bevacizumab, sorafenib, lenvatinib, regorafenib, cabozantinib, checkpoint inhibitors and tyrosine kinase inhibitors or anti-VEGF therapies\n* Other extrahepatic neoplasms occurring or in the last 3 years except for tumors resected with curative intent and without evidence of relapse for \\>3 years prior to signing informed consent and considered low risk of relapse\n* HIV infection\n* Failure to sign informed consent form","90 Years",{"count":19,"type":20},"The project comprises two research lines. In the line 1, human monoclonal antibodies toward SARS-CoV-2 will be generate and characterized by in vitro functional tests. In the line 2, in vitro tests will be performed to evaluate the efficency of immune response mediated by antibodies direct to specific tumor molecules.",[61,286],"Liver Tumours","2025-03-31",{"date":289,"type":37},"2025-04-06",{"date":291,"type":37},"2023-05-30",{"date":293,"type":20},"2027-02",{"name":295,"class":44},"Fondazione IRCCS Policlinico San Matteo di Pavia",{"id":297,"slug":298,"hasResults":11,"nctId":299,"briefTitle":300,"officialTitle":301,"acronym":302,"eligibilityCriteria":303,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":304,"targetDuration":4,"studyType":210,"phases":4,"briefSummary":306,"conditions":307,"keywords":309,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":313,"lastUpdatePostDateStruct":314,"startDateStruct":316,"completionDateStruct":318,"leadSponsor":320,"locationsCount":45},"100551316","viral-infection-of-hspc-impacts-hematopoiesis-100551316","NCT06458504","Viral Infection of HSPC Impacts Hematopoiesis","Virus-induced Immunosuppression Via Infection of Hematopoietic Progenitors","MEGAHOST","Inclusion Criteria:\n\nHIV patients :\n\n* HIV-positive patients with a negative or positive viral load.\n* managed at Ambroise Paré Hospital.\n* patients with a bone marrow biopsy or myelogram performed as part of their care.\n\nHealthy subjects without HIV - patients with a BM biopsy or myelogram performed as part of their care for a suspected hematological pathology.\n\nManagement at Ambroise Paré Hospital.\n\nExclusion Criteria:\n\n\\-",{"count":305,"type":20},45,"We propose to demonstrate that HIV-1 and SARS-CoV-2 are capable of targeting long-lived HSPC with self-renewal capacities. These progenitors, thus transformed into host cells, can give rise to a durable source of infected cells with an impact on hematopoiesis.",[308,89],"HIV-1",[308,89,310,311,312],"Hematopoietic Progenitors","Virus-induced","Immunosuppression","2025-03-17",{"date":315,"type":37},"2025-03-20",{"date":317,"type":37},"2024-10-25",{"date":319,"type":20},"2026-03",{"name":321,"class":44},"Assistance Publique - Hôpitaux de Paris",{"id":323,"slug":324,"hasResults":11,"nctId":325,"briefTitle":326,"officialTitle":327,"acronym":328,"eligibilityCriteria":329,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":16,"enrollmentInfo":330,"targetDuration":4,"studyType":21,"phases":332,"briefSummary":334,"conditions":335,"keywords":338,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":341,"lastUpdatePostDateStruct":342,"startDateStruct":344,"completionDateStruct":346,"leadSponsor":348,"locationsCount":350},"100575682","genome-analysis-of-human-endogenous-retroviruses-hervscovid19-100575682","NCT06775457","Genome Analysis of Human Endogenous Retroviruses (HERVs)(COVID19)","Genome Analysis of Human Endogenous Retroviruses (HERVs) and Gut Microbiota in Patients With SARS-CoV-2 Infection, Kawasaki Disease and Other Febrile and Inflammatory Diseases With Systemic Involvement in Pediatric Age.","HERV_COVID","Inclusion Criteria:\n\n* Pediatric patients, newly diagnosed with Kawasaki disease\n* Pediatric patients, newly diagnosed with Vasculitis\n* Pediatric patients, newly diagnosed with SARS-CoV-2 infection\n* Pediatric patients, newly diagnosed with febrile virosis\n* Pediatric patients with inflammatory diseases with systemic involvement\n\nExclusion Criteria:\n\n* None",{"count":331,"type":20},120,[333],"NA","Human Endogenous Retroviruses (HERVs) are ancient sequences that became integrated into our DNA during evolutionary processes.\n\nThe significance of their presence in DNA is still being studied, but HERVs appear to be involved in the regulation of the immune response.\n\nThe gut microbiota is the set of microorganisms that physiologically colonize the gastrointestinal tract. Progressively increasing attention is being paid to the gut microbiota and its potential role in diseases of various kinds. In particular, it has recently been shown how abnormalities in the microbiota can affect immune regulation by determining the occurrence of certain diseases. One objective of the study is to evaluate whether there is an association between the expression of HERVs and clinical manifestations in pediatric age in patients with various diseases such as Kawasaki Disease, IgA Vasculitis\u002FSchonlein-Henoch's Purpura, SARS-CoV-2 infection, or, finally, febrile virosis.\n\nAnother objective of the study is to evaluate whether there is an association between the presence of particular types of bacteria in the gut microbiota and clinical manifestations in pediatric age in patients with Kawasaki Disease, IgA Vasculitis\u002FSchonlein-Henoch purpura, SARS-CoV-2 infection or febrile virosis.\n\nThe results from this may open new perspectives for both the care and therapeutic management of children with these diseases.",[61,336,337],"Kawasaki Disease","Retrovirus Infection",[339,336,340],"SARS-COV2","Human Endogenous Retroviruses","2025-01-09",{"date":343,"type":37},"2025-01-15",{"date":345,"type":37},"2021-06-10",{"date":347,"type":20},"2025-12-31",{"name":349,"class":44},"IRCCS Azienda Ospedaliero-Universitaria di Bologna",5,{"id":352,"slug":353,"hasResults":11,"nctId":354,"briefTitle":355,"officialTitle":355,"acronym":89,"eligibilityCriteria":356,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":357,"targetDuration":4,"studyType":21,"phases":358,"briefSummary":359,"conditions":360,"keywords":362,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":364,"lastUpdatePostDateStruct":365,"startDateStruct":367,"completionDateStruct":369,"leadSponsor":370,"locationsCount":45},"100563013","extended-remdesivir-infusion-combined-with-nirmatrelvirritonavir-for-persistent-sars-cov-2-infection-in-immunocompromised-patients-100563013","NCT06610643","Extended Remdesivir Infusion Combined With Nirmatrelvir\u002FRitonavir for Persistent SARS-CoV-2 Infection in Immunocompromised Patients","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Receive B-cell depletion therapy or bendamustine within 6months\n* Laboratory confirmed SARS-CoV-2 infection\n* Symptoms onset within 72 hours\n* NIAID ordinal score 0-5 upon enrollment\n\nExclusion Criteria:\n\n* Prior use of any anti-SARS-CoV-2 agents within 2 weeks. Remdesivir or NMV\u002Fr initiated within 24 hours is acceptable\n* Life expectancy \\< 1 month\n* Previous adverse effect related to remdesivir or NMV\u002Fr\n* Concurrent use medicine with drug-drug interaction with NMV\u002Fr\n* Patients receiving intubation and mechanical ventilation\n* eGFR \\< 30\n* Child pugh score Class C\n* Any other condition that in the opinion of the investigator would jeopardize the safety or rights of a subject participating in the trial or would render the subject unable to comply with the protocol.",{"count":19,"type":20},[333],"To evaluate the safety and efficacy of extended remdesivir infusion, targeting on immunocompromised individuals who had positive SARS-CoV-2 PCR despite an oral antiviral agent prescription.",[159,89,361],"Immunocompromised",[363],"Extended RDV infusion combination therapy for SARS-CoV-2 infection in immunocompromised patients","2024-09-24",{"date":366,"type":37},"2024-09-25",{"date":368,"type":20},"2024-09-21",{"date":170,"type":20},{"name":371,"class":44},"National Taiwan University Hospital",{"id":373,"slug":374,"hasResults":11,"nctId":375,"briefTitle":376,"officialTitle":377,"acronym":378,"eligibilityCriteria":379,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":380,"targetDuration":4,"studyType":21,"phases":382,"briefSummary":383,"conditions":384,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":385,"lastUpdatePostDateStruct":386,"startDateStruct":388,"completionDateStruct":390,"leadSponsor":392,"locationsCount":4},"100416949","phase-2-to-evaluate-scta01-treatment-of-high-risk-outpatients-with-covid-19-100416949","NCT04709328","To Evaluate SCTA01 Treatment of High-risk Outpatients With COVID-19","An Adaptive, Randomized, Double-blinded, Placebo-controlled Phase II\u002FIII Trial of Monoclonal Antibody SCTA01 Against SARS-CoV-2 in High-Risk Outpatients With COVID-19 (MAOP3 Trial)","MAOP3","Inclusion Criteria:\n\n* Male or non-pregnant female adults, ≥18 years old of age at the time of randomization;\n* Participants should have at least one of COVID-19 risk factor;\n* Participants should have at least 2 COVID-19 related symptoms;\n* Has symptoms consistent with COVID-19 as determined by the investigator with onset ≤7 days before randomization;\n* First positive SARS-CoV-2 viral infection tested (PCR or antigen-based diagnostic tests) in samples collected ≤3 days prior to start of the infusion;\n* Participants are currently not hospitalized;\n* Participant (or legal authorized representative) has signed the ICF before any clinical activity related to SCTA01 trial;\n* Women with childbearing potential must agree to use effective contraceptive methods during the study period;\n* Patient should not participate in other clinical studies related to COVID-19 or SARS-CoV-2 infection.\n\nExclusion Criteria:\n\n* Have known allergies to any of the components used in the formulation of the SCTA01\u002Fplacebo;\n* Participants with a history of severe anaphylaxis, such as severe anaphylactic reaction, urticaria, and angioedema;\n* Have SpO2 ≤ 93% on room air at sea level or PaO2\u002FFiO2 \\\u003C 300, respiratory rate ≥30 per minute, heart rate ≥125 per minute (FDA);\n* Require mechanical ventilation or anticipated impending need for mechanical ventilation;\n* Suspected or proven serious bacterial, fungal, viral, or other infection (besides COVID-19) that in the opinion of the investigator could constitute a risk when taking part in this study;\n* Have any serious concomitant systemic disease, condition or disorder that, in the opinion of the investigator, should preclude participation in this study;\n* Have any co-morbidity requiring surgery within \\\u003C29 days, or that is considered life threatening within 29 days;\n* Have a history of previous SARS-CoV-2 infection;\n* Received convalescent plasma, COVID-19 vaccine, or anti-SARS-CoV-2 spike(S) protein targeted therapy;\n* Have participated in a clinical study involving an investigational intervention within past 30 days or 5-half lives of investigational product, whichever is longer;\n* Have received an investigational intervention for SARS-CoV-2 prophylaxis within 30 days before dosing;\n* Pregnant or lactating women;\n* Anticipated hospitalization or transfer to another medical site which is not a study site within 72 hours;\n* Participants unable to follow the protocol during the study;\n* Participants deemed inappropriate for enrollment by the investigator due to other factors.",{"count":381,"type":20},690,[86,56],"The study is a multicenter, adaptive, randomized, double-blinded and placebo-controlled Phase II\u002FIII clinical trial. It will be conducted at selected investigational sites globally. The study is comprised of 2 parts.",[159,89],"2021-03-24",{"date":387,"type":37},"2021-03-29",{"date":389,"type":20},"2021-03-28",{"date":391,"type":20},"2022-03-01",{"name":393,"class":121},"Sinocelltech Ltd."]